Towards investigation, development and introduction of cefiderocol in children: product brief

Overview

Cefiderocol was included in WHO’s PADO priority list because of its efficacy against multiple pathogens in the WHO bacterial priority pathogens list, its favourable resistance and cross-resistance profile and considering that clinical trials involving children are ongoing. This brief aims to provide a summary of cefiderocol’s characteristics, current and planned paediatric studies (including neonates) and initiatives to ensure prompt access for all people in need. It also proposes interventions that should be prioritized by researchers and funders for its development, as well as, more broadly for antibiotics that are much needed in children.